174 related articles for article (PubMed ID: 29403080)
1. Tumor suppressor CD99 is downregulated in plasma cell neoplasms lacking CCND1 translocation and distinguishes neoplastic from normal plasma cells and B-cell lymphomas with plasmacytic differentiation from primary plasma cell neoplasms.
Gao Q; Yellapantula V; Fenelus M; Pichardo J; Wang L; Landgren O; Dogan A; Roshal M
Mod Pathol; 2018 Jun; 31(6):881-889. PubMed ID: 29403080
[TBL] [Abstract][Full Text] [Related]
2. Immunophenotypic features by multiparameter flow cytometry can help distinguish low grade B-cell lymphomas with plasmacytic differentiation from plasma cell proliferative disorders with an unrelated clonal B-cell process.
Rosado FG; Morice WG; He R; Howard MT; Timm M; McPhail ED
Br J Haematol; 2015 May; 169(3):368-76. PubMed ID: 25644063
[TBL] [Abstract][Full Text] [Related]
3. Practical diagnostic approaches to composite plasma cell neoplasm and low grade B-cell lymphoma/clonal infiltrates in the bone marrow.
Hussein S; Gill K; Baer LN; Hoehn D; Mansukhani M; Jobanputra V; Bhagat G; Alobeid B
Hematol Oncol; 2015 Mar; 33(1):31-41. PubMed ID: 24395190
[TBL] [Abstract][Full Text] [Related]
4. Immunoreactivity of MIC2 (CD99) and terminal deoxynucleotidyl transferase in bone marrow clot and core specimens of acute myeloid leukemias and myelodysplastic syndromes.
Kang LC; Dunphy CH
Arch Pathol Lab Med; 2006 Feb; 130(2):153-7. PubMed ID: 16454553
[TBL] [Abstract][Full Text] [Related]
5. Cyclin D1 expression in B-cell lymphomas.
Gladkikh A; Potashnikova D; Korneva E; Khudoleeva O; Vorobjev I
Exp Hematol; 2010 Nov; 38(11):1047-57. PubMed ID: 20727381
[TBL] [Abstract][Full Text] [Related]
6. CD99 (MIC2) expression in paediatric B-lineage leukaemia/lymphoma reflects maturation-associated patterns of normal B-lymphopoiesis.
Dworzak MN; Fritsch G; Fleischer C; Printz D; Fröschl G; Buchinger P; Mann G; Gadner H
Br J Haematol; 1999 Jun; 105(3):690-5. PubMed ID: 10354133
[TBL] [Abstract][Full Text] [Related]
7. Tissue inhibitor of metalloproteinase 1 (TIMP-1) promotes plasmablastic differentiation of a Burkitt lymphoma cell line: implications in the pathogenesis of plasmacytic/plasmablastic tumors.
Guedez L; Martinez A; Zhao S; Vivero A; Pittaluga S; Stetler-Stevenson M; Raffeld M; Stetler-Stevenson WG
Blood; 2005 Feb; 105(4):1660-8. PubMed ID: 15479729
[TBL] [Abstract][Full Text] [Related]
8. Viral latent membrane protein 1 (LMP-1)-induced CD99 down-regulation in B cells leads to the generation of cells with Hodgkin's and Reed-Sternberg phenotype.
Kim SH; Shin YK; Lee IS; Bae YM; Sohn HW; Suh YH; Ree HJ; Rowe M; Park SH
Blood; 2000 Jan; 95(1):294-300. PubMed ID: 10607715
[TBL] [Abstract][Full Text] [Related]
9. p53 expression in large B-cell lymphomas with MYC extra copies and CD99 expression in large B-cell lymphomas in relation to MYC status.
Richardson AI; Zhang D; Woodroof J; Cui W
Hum Pathol; 2019 Apr; 86():21-31. PubMed ID: 30496802
[TBL] [Abstract][Full Text] [Related]
10. Anti-human CD99 antibody exerts potent antitumor effects in mantle cell lymphoma.
Takheaw N; Sittithumcharee G; Kariya R; Kasinrerk W; Okada S
Cancer Immunol Immunother; 2021 Jun; 70(6):1557-1567. PubMed ID: 33215253
[TBL] [Abstract][Full Text] [Related]
11. Loss of CD19 expression in B-cell neoplasms.
Masir N; Marafioti T; Jones M; Natkunam Y; Rüdiger T; Hansmann ML; Mason DY
Histopathology; 2006 Feb; 48(3):239-46. PubMed ID: 16430470
[TBL] [Abstract][Full Text] [Related]
12. TCL1 in B-cell tumors retains its normal b-cell pattern of regulation and is a marker of differentiation stage.
Herling M; Patel KA; Hsi ED; Chang KC; Rassidakis GZ; Ford R; Jones D
Am J Surg Pathol; 2007 Jul; 31(7):1123-9. PubMed ID: 17592280
[TBL] [Abstract][Full Text] [Related]
13. Early B-cell-specific inactivation of ATM synergizes with ectopic CyclinD1 expression to promote pre-germinal center B-cell lymphomas in mice.
Yamamoto K; Lee BJ; Li C; Dubois RL; Hobeika E; Bhagat G; Zha S
Leukemia; 2015 Jun; 29(6):1414-24. PubMed ID: 25676421
[TBL] [Abstract][Full Text] [Related]
14. CD99 Expression in Glioblastoma Molecular Subtypes and Role in Migration and Invasion.
Cardoso LC; Soares RDS; Laurentino TS; Lerario AM; Marie SKN; Oba-Shinjo SM
Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30845661
[TBL] [Abstract][Full Text] [Related]
15. miR-15a/16-1 deletion in activated B cells promotes plasma cell and mature B-cell neoplasms.
Sewastianik T; Straubhaar JR; Zhao JJ; Samur MK; Adler K; Tanton HE; Shanmugam V; Nadeem O; Dennis PS; Pillai V; Wang J; Jiang M; Lin J; Huang Y; Brooks D; Bouxsein M; Dorfman DM; Pinkus GS; Robbiani DF; Ghobrial IM; Budnik B; Jarolim P; Munshi NC; Anderson KC; Carrasco RD
Blood; 2021 Apr; 137(14):1905-1919. PubMed ID: 33751108
[TBL] [Abstract][Full Text] [Related]
16. Expression of the retinoblastoma protein in low-grade B-cell lymphoma: relationship to cyclin D1.
Zukerberg LR; Benedict WF; Arnold A; Dyson N; Harlow E; Harris NL
Blood; 1996 Jul; 88(1):268-76. PubMed ID: 8704183
[TBL] [Abstract][Full Text] [Related]
17. Immunophenotypic and laboratory features of t(11;14)(q13;q32)-positive plasma cell neoplasms.
Shi M; Ternus JA; Ketterling RP; Jevremovic D; McPhail ED
Leuk Lymphoma; 2018 Aug; 59(8):1913-1919. PubMed ID: 29214874
[TBL] [Abstract][Full Text] [Related]
18. [The clinic and pathologic significance of plasma cell myeloma with CCND1].
Sun Q; An G; Liu E; Li Z; Zhang H; Yang Q; Sun F; Ma Y; Xian M; Zhang P; Ru K
Zhonghua Xue Ye Xue Za Zhi; 2015 Sep; 36(9):775-9. PubMed ID: 26462780
[TBL] [Abstract][Full Text] [Related]
19. Expression of the interferon regulatory factor 8/ICSBP-1 in human reactive lymphoid tissues and B-cell lymphomas: a novel germinal center marker.
Martinez A; Pittaluga S; Rudelius M; Davies-Hill T; Sebasigari D; Fountaine TJ; Hewitt S; Jaffe ES; Raffeld M
Am J Surg Pathol; 2008 Aug; 32(8):1190-200. PubMed ID: 18580679
[TBL] [Abstract][Full Text] [Related]
20. MMP-9 affects gene expression in chronic lymphocytic leukemia revealing CD99 as an MMP-9 target and a novel partner in malignant cell migration/arrest.
Aguilera-Montilla N; Bailón E; Uceda-Castro R; Ugarte-Berzal E; Santos A; Gutiérrez-González A; Pérez-Sánchez C; Van den Steen PE; Opdenakker G; García-Marco JA; García-Pardo A
Oncogene; 2019 Jun; 38(23):4605-4619. PubMed ID: 30760844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
